Details of the Drug Combination

General Information of Drug Combination (ID: DC25P1W)

Drug Combination Name
Teriparatide Alendronate
Indication
Disease Entry Status REF
Osteoporosis Phase 1 [1]
Component Drugs Teriparatide   DMMC45B Alendronate   DMY2KX9
Peptide Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Teriparatide
Disease Entry ICD 11 Status REF
Exostosis N.A. Approved [2]
Myelofibrosis 2A20.2 Approved [2]
Osteogenesis imperfecta LD24.K0 Approved [3]
Osteoporosis FB83.0 Approved [2]
Psoriatic disorder EA90 Discontinued in Phase 2 [4]
Autosomal dominant hypocalcemia 5A50.0Y Investigative [2]
Teriparatide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Parathyroid hormone (PTH) TT6F7GZ PTHY_HUMAN Modulator [7]
------------------------------------------------------------------------------------
Indication(s) of Alendronate
Disease Entry ICD 11 Status REF
Bone Paget disease N.A. Approved [5]
Exostosis N.A. Approved [5]
Osteoporosis FB83.0 Approved [6]
Paget's disease FB85 Approved [6]
Prostate adenocarcinoma N.A. Approved [5]
Alendronate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Geranyltranstransferase (FDPS) TTIKWV4 FPPS_HUMAN Modulator [7]
------------------------------------------------------------------------------------
Alendronate Interacts with 6 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Collagen alpha-1(II) chain (COL2A1) OT5E59C8 CO2A1_HUMAN Decreases Expression [9]
Collagen alpha-1(III) chain (COL3A1) OTT1EMLM CO3A1_HUMAN Decreases Expression [9]
Osteocalcin (BGLAP) OTK1YLWQ OSTCN_HUMAN Decreases Expression [9]
72 kDa type IV collagenase (MMP2) OT5NIWA2 MMP2_HUMAN Decreases Expression [10]
Collagen alpha-3(V) chain (COL5A3) OTCGC4DM CO5A3_HUMAN Decreases Expression [9]
Ras-related protein Rap-1A (RAP1A) OT5RH6TI RAP1A_HUMAN Decreases Prenylation [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DOT(s)

References

1 ClinicalTrials.gov (NCT00000400) Alendronate and/or Parathyroid Hormone for Osteoporosis
2 Teriparatide FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4448).
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030730)
5 Alendronate FDA Label
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3141).
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes. Clin Endocrinol (Oxf). 2003 Mar;58(3):365-71. doi: 10.1046/j.1365-2265.2003.01724.x.
9 Expression profile and synthesis of different collagen types I, II, III, and V of human gingival fibroblasts, osteoblasts, and SaOS-2 cells after bisphosphonate treatment. Clin Oral Investig. 2010 Feb;14(1):51-8. doi: 10.1007/s00784-009-0312-2. Epub 2009 Jul 14.
10 Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer. 2004 May;42(5):410-5. doi: 10.1002/pbc.20019.
11 Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone. 2001 Oct;29(4):336-43. doi: 10.1016/s8756-3282(01)00589-0.